This trial will assess if CSL312 is a safe and effective treatment for idiopathic pulmonary fibrosis.
8 Primary · 9 Secondary · Reporting Duration: Up to 22 weeks
Experimental Treatment
Non-Treatment Group
80 Total Participants · 2 Treatment Groups
Primary Treatment: CSL312 · Has Placebo Group · Phase 2
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: